5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Investing.com -- SciSparc Ltd. (NASDAQ:SPRC) stock rose 2.6% on Thursday after the clinical-stage pharmaceutical company announced plans to launch a new initiative focused on 3D protein modeling using quantum computing technology.
The company’s board of directors resolved on September 16, 2025, to initiate the program, which aims to transform drug discovery by potentially achieving higher accuracy in predicting protein structures and their interactions with ligands.
SciSparc, which specializes in developing therapies for central nervous system disorders, plans to leverage quantum computing to overcome limitations of traditional computing methods in modeling protein dynamics. The technology could potentially simulate the energy dynamics of proteins with greater precision than classical computing approaches.
The initiative will focus on developing quantum-enabled tools to predict protein folding, model protein-ligand interactions, and accelerate drug discovery through precise predictions. The company intends to form a dedicated research team and collaborate with experts in quantum computing and structural biology.
Initial efforts will target applications in drug discovery for neurological and rare diseases, areas where SciSparc already has established expertise. The company expects to incorporate a new wholly owned Israeli subsidiary to operate the initiative.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.